These great growth stocks have much further to go

Royston Wild looks at two stocks with hot earnings prospects.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

FTSE 250 pharma play Dechra Pharmaceuticals (LSE: DPH) has proved a stellar performer so far in 2017.

Dechra has gained 35% in value, the company hitting peaks above £19.50 per share in the process before settling lower more recently. However, I see this mild reversal as a temporary pause for breath and an opportunity for dip buyers to pile-in, and particularly for those seeking hot growth stocks .

City brokers expect Dechra to have put the pedal to the metal and generate earnings growth of 45% in the year to June 2017, up from the 7% advance generated last year. And an extra, meaty 16% rise is anticipated for fiscal 2018.

A forward P/E multiple of 24.9 times may appear a tad heady at face value, soaring above the widely-considered value benchmark of 15 times. But I reckon a stock of Dechra’s quality deserves such a premium.

Medical marvel

Through an aggressive strategy of clever acquisitions and licensing deals, Dechra has established itself as a major global force in the animal care market for both pets and farm animals.

The company made further steps in March when it announced it had inked a licensing deal with Australia-based Animal Ethics to sell the Tri-Solfen product in all geographies barring Australia and New Zealand. The drug is administered to anaesthetise, relieve pain, control bleeding and battle infection during routine treatments in livestock.

And at the same time, Dechra announced that it had acquired 33% of the share capital of Medical Ethics for $18m, the parent company of Animal Ethics.

With the balance sheet robust enough to facilitate more action on the M&A front, and recent purchases also boosting the company’s exciting product pipeline, I reckon Dechra has what it takes to deliver stunning returns in the years ahead.

Major glazier

Tyman (LSE: TYMN) is another brilliant growth stock enjoying brilliant momentum — the door and window builder has risen 33% since the bells rang-in New Year’s Day, and it topped out at a record peak above 365p per share on Friday.

Like Dechra, Tyman has been engaged in lively acquisition activity in recent times, with the acquisition of Giesse and Bilco in particular bolstering the company’s position in Europe and North America respectively. And solid economic growth in these territories looks likely to fire demand for Tyman’s products soundly higher.

The number crunchers certainly expect Tyman’s long-running growth story to continue, and expansion of 10% and 8% is anticipated for 2017 and 2018. Consequently the business trades on a forward earnings multiple of 13.2 times, a figure that can be expected to support further share price advances should — as I expect — trading continue to impress.

Tyman advised last month that it has got off to “a solid start” so far in 2017, with revenues rising 31% from the beginning of the year to May 12, thanks to the impact of sterling weakness and sales generated from recent acquisitions. And investors can expect the top line to pick up the pace once the seasonal quietness in its Northern Hemisphere markets draws to a close.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

2 red-hot UK growth stocks to consider buying in April

These two growth stocks are performing well, but can they continue to deliver for investors through 2024 and beyond?

Read more »

Charticle

Is JD Sports Fashion one of the FTSE 100’s best value stocks? Here’s what the charts say!

The JD Sports Fashion share price remains a wild ride during the first quarter. Could it be one of the…

Read more »

Investing Articles

Could the JD Sports Fashion share price double in the next five years?

The JD Sports Fashion share price has nearly halved in the past five years. Our writer thinks a proven business…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

If interest rate cuts are coming, I think these UK growth stocks could soar!

Falling interest could be great news for UK growth stocks, especially those that have been under the cosh recently. Paul…

Read more »

Investing Articles

Are these the best stocks to buy on the FTSE right now?

With the UK stock market on the way to hitting new highs, this Fool is considering which are the best…

Read more »

Petrochemical engineer working at night with digital tablet inside oil and gas refinery plant
Investing Articles

Can the Centrica dividend keep on growing?

Christopher Ruane considers some positive factors that might see continued growth in the Centrica dividend -- as well as some…

Read more »

Smiling family of four enjoying breakfast at sunrise while camping
Investing Articles

How I’d turn my £12,000 of savings into passive income of £1,275 a month

This Fool is considering a strategy that he believes can help him achieve a stable passive income stream with a…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

2 top FTSE 250 investment trusts trading at attractive discounts!

This pair of discounted FTSE 250 trusts appear to be on sale right now. Here's why I'd scoop up their…

Read more »